N(4)-Hydroxycytidine CAS 3258-02-4 EIDD-1931 NHC High Quality
Nye ya na ịdị ọcha dị elu yana ịdị mma kwụsie ike
Aha Chemical: N (4)-Hydroxycytidine;EIDD-1931 (NHC)
Nọmba: 3258-02-4
Metabolite na-arụ ọrụ nke Molnupiravir, ihe mgbochi COVID-19 na-ekwe nkwa
| Aha Chemical | N (4) - Hydroxycytidine |
| Ụdị okwu | EIDD-1931 (NHC);β-D-N4-Hydroxycytidine |
| Nọmba CAS | 3258-02-4 |
| Nọmba CAT | RF-PI309 |
| Ọnọdụ Ahịa | N'ọkwa, Mpụta Ihe ruru Kilogram |
| Usoro ihe omimi | C9H13N3O6 |
| Ibu molekụla | 259.22 |
| Ebe Na-agbaze | 169.0 ~ 172.0 ℃ |
| Solubility | Soluble na 100 mM na DMSO na ruo 50 mM na mmiri |
| Njupụta | 1.93±0.1 g/cm3 |
| Ụdị | Ruifu Chemical |
| Ihe | Nkọwapụta |
| Ọdịdị | Ọcha ka Gbanyụọ-Ọcha ntụ ntụ |
| NMR | Nkwekọ na Structure |
| Ụzọ ịdị ọcha / nyocha | > 98% (HPLC) |
| Ọnwụ na ihicha | ≤1.0% |
| Otu adịghị ọcha | ≤0.50% |
| Ọla dị arọ | ≤20ppm |
| Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
| Ojiji | Metabolite na-arụ ọrụ nke Molnupiravir (EIDD-2801), ihe mgbochi COVID-19. |
ngwugwu: Kalama, Aluminom foil bag, kaadiboodu drum, 25kg / Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ọkụ, mmiri mmiri na ụmụ ahụhụ.
N (4) -Hydroxycytidine (EIDD-1931, β-d-N4-hydroxycytidine, NHC, CAS 3258-02-4) bụ metabolite na-arụ ọrụ nke EIDD-2801, onye na-egbochi COVID-19 na-ekwe nkwa.EIDD-1931 (NHC) nwere nnukwu ọrụ mgbochi mgbochi megide ọtụtụ coronaviruses, gụnyere SARS-CoV-2, MERS-CoV, SARS-CoV, yana zoonotic otu 2b ma ọ bụ 2c Bat-CoVs nwere nkezi IC50 nke 0.15 μM, yana yana ike na-abawanye megide mmụgharị na-eguzogide coronavirus na nucleoside analog inhibitor remdesivir.N'ime ụmụ oke bu ọrịa SARS-CoV ma ọ bụ MERS-CoV, ma prophylactic na ọgwụgwọ ọgwụgwọ nke Molnupiravir (EIDD-2801), NHC-prodrug nke ọnụ ọnụ (β-D-N4-hydroxycytidine-5'-isopropyl ester), kwalitere ọrụ akpa ume. , na mbelata nje titer na mbelata ahụ.MERS-CoV mbelata na vitro na in vivo jikọtara ya na mmụba mgbanwe mgbanwe ugboro na nje mana ọ bụghị cell RNA, na-akwado usoro nke mutagenesis na-egbu egbu na CoV.Ike nke NHC/EIDD-2801 megide ọtụtụ coronaviruses na ọnụnụ bioavailability na-egosipụta ike ya dị ka ọgwụ mgbochi dị irè megide SARS-CoV-2 na coronaviruses zoonotic ndị ọzọ n'ọdịnihu.
